Search results for: Host
#34118782 2021/06/05 To Up
Selenium respiration in anaerobic bacteria: Does energy generation pay off?Selenium (Se) respiration in bacteria was revealed for the first time at the end of 1980s. Although thermodynamically-favorable, energy-dense and documented in phylogenetically-diverse bacteria, this metabolic process appears to be accompanied by a number of challenges and numerous unanswered questions. Selenium oxyanions, SeO and SeO, are reduced to elemental Se (Se) through anaerobic respiration, the end product being solid and displaying a considerable size (up to 500Â nm) at the bacterial scale. Compared to other electron acceptors used in anaerobic respiration (e.g. N, S, Fe, Mn, and As), Se is one of the few elements whose end product is solid. Furthermore, unlike other known bacterial intracellular accumulations such as volutin (inorganic polyphosphate), S, glycogen or magnetite, Se has not been shown to play a nutritional or ecological role for its host. In the context of anaerobic respiration of Se oxyanions, biogenic Se appears to be a by-product, a waste that needs proper handling, and this raises the question of the evolutionary implications of this process. Why would bacteria use a respiratory substrate that is useful, in the first place, and then highly detrimental? Interestingly, in certain artificial ecosystems (e.g. upflow bioreactors) Se might help bacterial cells to increase their density and buoyancy and thus avoid biomass wash-out, ensuring survival. This review article provides an in-depth analysis of selenium respiration (model selenium respiring bacteria, thermodynamics, respiratory enzymes, and genetic determinants), complemented by an extensive discussion about the evolutionary implications and the properties of biogenic Se using published and original/unpublished results.
Lucian C Staicu, Larry L Barton
1848 related Products with: Selenium respiration in anaerobic bacteria: Does energy generation pay off?96 tests 5 G100ug Lyophilized100 ug2 100 assays100 μg250ul48 assays 100 μg
#34118728 2021/06/09 To Up
Vaccine hesitancy in migrant communities: a rapid review of latest evidence.B
Akhenaten Siankam Tankwanchi, Brett Bowman, Michelle Garrison, Heidi Larson, Charles Shey Wiysonge
2620 related Products with: Vaccine hesitancy in migrant communities: a rapid review of latest evidence.400Tests1 Set96T100 μg100 μg100 μg100 μg25 Bags/Unit100ul100 assays
No related Items
#34118489 2021/06/09 To Up
Acute experimental barrier injury triggers ulcerative colitis specific innate hyper-responsiveness and ulcerative colitis-type microbiome changes in humans.The trigger hypothesis opens the possibility of anti-flare-initiation therapies by stating that ulcerative colitis (UC) flares originates from inadequate responses to acute mucosal injuries. However, experimental evidence is restricted by a limited use of suitable human models. We thus aimed to investigate the acute mucosal barrier injury responses in humans with and without UC using an experimental injury model.
Jakob Benedict Seidelin, Martin Iain Bahl, Tine Rask Licht, Benjamin E Mead, Jeffrey M Karp, Jens Vilstrup Johansen, Lene Buhl Riis, Marina RamÃrez Galera, Anders Woetmann, Jacob Tveiten Bjerrum
1039 related Products with: Acute experimental barrier injury triggers ulcerative colitis specific innate hyper-responsiveness and ulcerative colitis-type microbiome changes in humans.4 Membranes/Box2 Pieces/Box1 mg250 ml1 mL4 Membranes/Box2 Pieces/Box96T50ug4 Arrays/Slide
#34118469 2021/06/09 To Up
Long-term follow-up of ruxolitinib in the treatment of steroid-refractory chronic graft-versus-host disease (GVHD).Chronic graft-versus-host disease (cGVHD) remains a major barrier to a successful hematopoietic stem cell transplantation (HSCT); in cases refractory to first-line therapy with steroids, there is no standard of care for second-line therapy. As such, ruxolitinib is a promising drug in this scenario. We retrospectively analyzed its efficacy and safety as treatment of steroid-refractory cGVHD in 35 patients from two transplant centers, with the longest follow-up described to date. Evaluated patients had a median of 3 organs affected (1-7), with most (64%) having moderate cGVHD. The median number of previous therapy lines was two (1-6). Overall response rate was 89% (complete response, 26%) after a median of 4 weeks of therapy. Median follow-up was 43 months (range 11-59). At follow-up, of the 27 patients still alive, 18 patients (67%) are free of any immunosuppression, and 6 (22%) are using ruxolitinib as the only immunosuppressive drug. Failure-free survival was 77.1%, 68.6%, 54% and 51,4% at 6, 12, 24 and 36 months, respectively. Median overall survival (OS) was not reached. Toxicities were mostly hematological and resolved after dose reduction in most cases. In conclusion, our data, which represent the cohort of patients with cGVHD treated with ruxolitinib with the longest follow-up to date, support the use of this drug as a safe and effective option for refractory cGVHD.
Aliana Meneses Ferreira, Roberta Shcolnik Szor, Vinicius Campos Molla, Maria Cristina Seiwald, Pedro Arruda de Moraes, Ana Rita Brito Medeiros da Fonseca, Erick Menezes Xavier, Mariana Gomes Serpa, Luciana Tucunduva, Yana Novis, Celso Arrais-Rodrigues
1726 related Products with: Long-term follow-up of ruxolitinib in the treatment of steroid-refractory chronic graft-versus-host disease (GVHD).50 UG 0.1 mg 100 μg100 μg50 500 tests100 μg100 μg100 ul100 ul96 tests
#34118468 2021/06/09 To Up
Enhanced immune reconstitution of Î³Î´ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.: Î³Î´ T cells and MRD+ AML.Minimal residual disease (MRD) prior to allogeneic stem cell transplantation (allo-SCT) in AML is a poor risk factor for outcome. The Î³Î´ T cells represents a unique minority lymphocyte population which is preferentially located in peripheral tissues, can recognize antigens in non-MHC restricted manner and plays a "bridging" role between innate and adaptive immune system.
Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Ulrike Fritsche-Friedland, Dietlinde Janson, Francis Ayuk, Christine Wolschke, Ulrike Bacher, Nicolaus KrÃ¶ger
2247 related Products with: Enhanced immune reconstitution of Î³Î´ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.: Î³Î´ T cells and MRD+ AML.96 tests96 tests1mg25 TESTS1 mg100ml100 extractions0.1ml (1mg/ml)1.00 flask
#34118385 2021/06/09 To Up
Compctutational identification of putative common genomic drug and vaccine targets in Mycoplasma genitalium.Mycoplasma genitalium is an obligate intracellular bacterium that is responsible for several sexually transmitted infections, including non-gonococcal urethritis in men and several inflammatory reproductive tract syndromes in women. Here, we applied subtractive genomics and reverse vaccinology approaches for in silico prediction of potential vaccine and drug targets against five strains of M. genitalium. We identified 403 genes shared by all five strains, from which 104 non-host homologous proteins were selected, comprising of 44 exposed/secreted/membrane proteins and 60 cytoplasmic proteins. Based on the essentiality, functionality, and structure-based binding affinity, we finally predicted 19 (14 novel) putative vaccine and 7 (2 novel) candidate drug targets. The docking analysis showed six molecules from the ZINC database as promising drug candidates against the identified targets. Altogether, both vaccine candidates and drug targets identified here may contribute to the future development of therapeutic strategies to control the spread of M. genitalium worldwide.
Wylerson G Nogueira, Arun Kumar Jaiswal, Sandeep Tiwari, Rommel T J Ramos, Preetam Ghosh, Debmalya Barh, Vasco Azevedo, Siomar C Soares
1678 related Products with: Compctutational identification of putative common genomic drug and vaccine targets in Mycoplasma genitalium.100 assays300 units100 assays100 assays100 assays100 assays100 assays100 assays100 assays100 assays100 assays100 assays
#34118383 2021/06/09 To Up
Genome sequence of the cardiopulmonary canid nematode Angiostrongylus vasorum reveals species-specific genes with potential involvement in coagulopathy.Angiostrongylus vasorum is an emerging parasitic nematode of canids and causes respiratory distress, bleeding, and other signs in dogs. Despite its clinical importance, the molecular toolbox allowing the study of the parasite is incomplete. To address this gap, we have sequenced its nuclear genome using Oxford nanopore sequencing, polished with Illumina reads. The size of the final genome is 280â¯Mb comprising 468 contigs, with an N50 value of 1.68â¯Mb and a BUSCO score of 93.5%. Ninety-three percent of 13,766 predicted genes were assigned to putative functions. Three folate carriers were found exclusively in A. vasorum, with potential involvement in host coagulopathy. A screen for previously identified vaccine candidates, the aminopeptidase H11 and the somatic protein rHc23, revealed homologs in A. vasorum. The genome sequence will provide a foundation for the development of new tools against canine angiostrongylosis, supporting the identification of potential drug and vaccine targets.
Annageldi Tayyrov, Nina Gillis-Germitsch, Lucienne Tritten, Manuela Schnyder
2325 related Products with: Genome sequence of the cardiopulmonary canid nematode Angiostrongylus vasorum reveals species-specific genes with potential involvement in coagulopathy.25 µg4 Membranes/Box2 Pieces/Box4 Membranes/Box2 Pieces/Box4 Arrays/Slide1 ml4 Arrays/Slide 100ul2 Pieces/Box
#34118360 2021/06/09 To Up
Zoonotic and Reverse Zoonotic Transmissibility of SARS-CoV-2.The Coronavirus Disease 2019 (COVID-19) is the first known pandemic caused by a coronavirus. Its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), appears to be capable of infecting different mammalian species. Recent detections of this virus in pet, zoo, wild, and farm animals have compelled inquiry regarding the zoonotic (animal-to-human) and reverse zoonotic (human-to-animal) transmissibility of SARS-CoV-2 with the potential of COVID-19 pandemic evolving into a panzootic. It is important to monitor the global spread of disease and to assess the significance of genomic changes to support prevention and control efforts during a pandemic. An understanding of the SARS-CoV-2 epidemiology provides opportunities to prevent the risk of repeated re-infection of humans and requires a robust One Health-based investigation. This review paper describes the known properties and the existing gaps in scientific knowledge about the zoonotic and reverse zoonotic transmissibility of the novel virus SARS-CoV-2 and the COVID-19 disease it causes.
Iryna V Goraichuk, Vasiliy Arefiev, Borys T Stegniy, Anton P Gerilovych100 ug/vial500 mg50 ug Product tipe: Antib200 25 mg 5 G10010 mg100ug500100 µg
#34118359 2021/06/09 To Up
Positive Selection as a Key Player for SARS-CoV-2 Pathogenicity: Insights into ORF1ab, S and E genes.The human Î²-coronavirus SARS-CoV-2 epidemic started in late December 2019 in Wuhan, China. It causes Covid-19 disease which has become pandemic. Each of the five-known human Î²-coronaviruses has four major structural proteins (E, M, N and S) and 16 non-structural proteins encoded by ORF1a and ORF1b together (ORF1ab) that are involved in virus pathogenicity and infectivity. Here, we performed detailed positive selection analyses for those six genes among the four previously known human Î²-coronaviruses and within 38 SARS-CoV-2 genomes to assess signatures of adaptive evolution using maximum likelihood approaches. Our results suggest that three genes (E, S and ORF1ab genes) are under strong signatures of positive selection among human Î²-coronavirus, influencing codons that are located in functional important protein domains. The E protein-coding gene showed signatures of positive selection in two sites, Asp 66 and Ser 68, located inside a putative transmembrane Î±-helical domain C-terminal part, which is preferentially composed by hydrophilic residues. Such Asp and Ser sites substitutions (hydrophilic residues) increase the stability of the transmembrane domain in SARS-CoV-2. Moreover, substitutions in the spike (S) protein S1 N-terminal domain have been found, all of them were located on the S protein surface, suggesting their importance in viral transmissibility and survival. Furthermore, evidence of strong positive selection was detected in three of the SARS-CoV-2 nonstructural proteins (NSP1, NSP3, NSP16), which are encoded by ORF1ab and play vital roles in suppressing host translation machinery, viral replication and transcription and inhibiting the host immune response. These results are insightful to assess the role of positive selection in the SARS-CoV-2 encoded proteins, which will allow to better understand the virulent pathogenicity of the virus and potentially identifying targets for drug or vaccine strategy design.
Mohamed Emam, Mariam Oweda, Agostinho Antunes, Mohamed El-Hadidi
2894 related Products with: Positive Selection as a Key Player for SARS-CoV-2 Pathogenicity: Insights into ORF1ab, S and E genes.1 g100tests1,000 tests100ug Lyophilized
#34118347 2021/06/09 To Up
Recent Advances in Potential Drug Therapies Combating COVID-19 and Related Coronaviruses-A Perspective.Coronaviruses (CoVs) are a large family of viruses responsible for the severe pathophysiological effects on human health. The most severe outbreak includes Severe Acute Respiratory Syndrome (SARS-CoV), Middle East Respiratory Syndrome (MERS-CoV) and Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 poses major challenges to clinical management because no specific FDA-approved therapy yet to be available. Thus, the existing therapies are being used for the treatment of COVID-19, which are under clinical trials and compassionate use, based on in vitro and in silico studies. In this review, we summarize the potential therapies utilizing small molecules, bioactive compounds, nucleoside and nucleotide analogs, peptides, antibodies, natural products, and synthetic compounds targeting the complex molecular signaling network involved in COVID-19. In this reviewï¼230 natural and chemically synthesized drug therapies are described with their recent advances in research and development being done in terms of their chemical, structural and functional properties. This review focuses on possible targets for viral cells, viral proteins, viral replication, and different molecular pathways for the discovery of novel viral- and host-based therapeutic targets against SARS-CoV-2.
Shivraj Hariram Nile, Arti Nile, Shivkumar Jalde, Guoyin Kai
1026 related Products with: Recent Advances in Potential Drug Therapies Combating COVID-19 and Related Coronaviruses-A Perspective.5 mg100 assays2 Pieces/Box100 assays100 assays100 assays2 Pieces/Box100 assays100 assays100 assays2 Pieces/Box100 assays
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia